NEWLAND PHARMACEUTICAL CO., LTD

The company is mainly engaged in the R&D, production and sales of APIs and pharmaceutical intermediates. At present, the main products are Naphazoline, Hydrochloride, Lidocaine HCL, Lidocaine, Ropivacaine HCL, Moxifloxacin HCL, Gatifloxacin, Vildagliptin, Esomeprazole Magnesium, Esomeprazole Sodium, Tadalafil, Chlorpheniramine Maleate, Febuxostat, Clopidogrel Bisulfate, D(-)-P-Hydroxyphenylglycine, D(-)-P-Hydroxyphenylglycine Dane Salt, Methyl D-(-)-4-hydroxy-phenylglycinate, p-toluenesulfonic acid (monohydrate), etc. In order to adapt to the implementation of formulation and API projects under the system of the pharmaceutical companies being holders, give full play to the company's advantages in production and service , and strengthen pharmaceutical companies’ ability to adapt to the requirements of cost control and efficiency improvement under the national implementation of a centralized procurement system, the company adopts CMO and CDMO business models to help pharmaceutical companies improve R&D production efficiency, shorten R&D production cycles, reduce R&D production costs, and accelerate product introduction. The project is located in the Biological Industrial Park of Changge City Industrial Cluster Area, with a total investment of 360 million yuan and a planned area of 10 hectares. The construction includes two parts: an API R&D service platform and an API customized production base. The project, aiming to be a a green production base of featured APIs in China, includes the construction of plants and supporting facilities required for the R&D and production of APIs, the purchase of more than 200 equipment (such as intelligent integrated continuous reaction systems, automated separation systems, condensers, mixers, GCs, LCs, mass spectrometers and so on), the set-up of an intelligent API R&D and production system, the formation of a team of high-quality professionals.